SIRPA and neoplasm: The in vivo anti-tumor activity of NILK-2401 was investigated in a mouse xenograft model, using SNU-C1 as target cells, as well as in a syngeneic model using human SIRPα/human CD47 transgenic mice with MC38 transfected with human CEACAM5 and human CD47 (Figure 6).